Originally published by our sister publication Infectious Disease Special Edition
By Landon Gray
The phase 3 Mosaico HIV vaccine clinical trial was discontinued because evidence of efficacy was lacking, according to a statement released by Janssen and its global partners.
Although the vaccination regimen was not effective in preventing HIV infection compared with placebo, according to the study’s independent data and safety monitoring board (DSMB), no safety issues were identified (